Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05495178
Other study ID # hepatobiliary manifestations
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2013
Est. completion date June 1, 2022

Study information

Verified date October 2022
Source Zagazig University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Several studies using different methodological approach have revealed incomplete, old and conflicting data on the course of hepatobiliary manifestations after surgery. authors conducted a prospective observational study to evaluate the role of LRP on the course of hepatobiliary manifestations for a better knowledge of these manifestations that is necessary to improve their management.also, to evaluate the role of surgery on prevention of liver damage from progression of the disease.


Description:

Inflammatory bowel disease (IBD) prevalence is expected to reach 1% of the population in many regions over the next decade. despite the fact that the primary clinical manifestations of IBD are centred in the gastrointestinal tract, 25-40% of IBD patients develop at least one extraintestinal manifestation (EIM). Hepatobiliary manifestations constitute one of the most common EIMs in IBD . Hepatobiliary manifestations are much more commonly associated with ulcerative colitis (UC) and include primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), fatty liver, cholelithiasis, primary biliary cholangitis, portal vein thrombosis, and hepatic abscess. Most UC patients can be managed medically, but a minority requires proctocolectomy. Two-stage laparoscopic proctocolectomy (LPC) with ileal pouch-anal anastomosis (IPAA) is a cure for colitis, but its effect on hepatobiliary diseases is controversial.


Recruitment information / eligibility

Status Completed
Enrollment 167
Est. completion date June 1, 2022
Est. primary completion date June 1, 2018
Accepts healthy volunteers
Gender All
Age group 18 Years to 69 Years
Eligibility Inclusion Criteria: - patients between 18-69 years, - both sex diagnosed as ulcerative colitis with at least one hepatobiliary manifestation - underwent laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis - with or without gallstones. Exclusion Criteria: - age<18 years or > 69 years, - alcohol abuse, - pregnancy, - severe heart failure or type II diabetes mellitus (defined as established diagnosis, HbA1c > 6.4%, non-fasting glucose level > 180 mg/dL, or on antidiabetic medication), - development of complications or death related to the operation of LRP , - liver toxicity of IBD-related medications., - chronic viral hepatitis, - haemochromatosis, - Wilson's disease,

Study Design


Intervention

Procedure:
laparoscopic restorative proctocolectomy
laparoscopic restorative proctocolectomy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Zagazig University

Outcome

Type Measure Description Time frame Safety issue
Primary severity of hepatobiliary manifestations after colectomy severity of hepatobiliary manifestations are measured by abdominal ultrasonography,liver biopsy ,CT and MRCP 4 years
See also
  Status Clinical Trial Phase
Completed NCT02197481 - Usefulness of BiClamp Forceps for Liver Resection: A Randomized Clinical Trial Phase 3
Terminated NCT03754452 - Evaluation of the Sarcopenia in Hepatobiliary Surgery
Completed NCT01918813 - Risk of Methicillin-resistant S.Aureus (MRSA) Infections in MRSA Carrier Under Introduction of Rapid MRSA Screening N/A
Completed NCT05481398 - A Randomized Controlled Trial Evaluating the Role of Negative Pressure Wound Therapy (NPWT) for Incisional Surgical Site Infections in Patients Undergoing Hepatopancreatobiliary Surgery N/A
Active, not recruiting NCT05682105 - Detection of Jaundice From Ocular Images Via Deep Learning
Completed NCT04213183 - Screening and Identifying Hepatobiliary Diseases Via Deep Learning Using Ocular Images
Not yet recruiting NCT03898765 - Dry Blood Spot Screening Test for Biliary Atresia(DBS-SCReBA) N/A